GlassScriptPhysician profile
Kevin Tin
NPI 1174812044
$167,800.21
in general payments reported to CMS, 2019-2025
42 companies · $53K in 2025
The $53K reported for 2025 was more than what 97% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $862 · 2020: $8,262 · 2021: $32K · 2022: $8,619 · 2023: $20K · 2024: $46K · 2025: $53K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $101K · Food and Beverage: $12K · Consulting Fee: $2,853 · Travel and Lodging: $1,966.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $101,205.50 |
| Food and Beverage | $12,420.18 |
| Consulting Fee | $2,852.50 |
| Travel and Lodging | $1,965.61 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $55,724.52 | 2019-2025 | Vemlidy |
| Abbvie INC. | $34,036.45 | 2019-2025 | Creon, Linzess, Rinvoq |
| Phathom Pharmaceuticals, INC. | $32,952.03 | 2023-2025 | Voquezna |
| Madrigal Pharmaceuticals | $31,031.67 | 2024-2025 | Rezdiffra, Resmetirom |
| Medtronic, INC. | $7,951.05 | 2021-2023 | Pillcam |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,707.68 | 2019-2025 | Xifaxan, Trulance |
| Ardelyx, INC. | $400.30 | 2022-2025 | Ibsrela |
| Ibsa Pharma INC. | $378.85 | 2022-2023 | Licart, Tirosint, Licart |
| Esperion Therapeutics, INC. | $370.63 | 2021-2022 | |
| Qol Medical, LLC | $297.21 | 2024-2025 | Sucraid, Sucraid |
| Janssen Biotech, INC. | $258.50 | 2022-2025 | Tremfya, Stelara, Simponi |
| Intra-Sana Laboratories | $213.35 | 2022-2024 | Reltone 400 Mg, Reltone 200 Mg, Glycate |
| Amgen INC. | $211.52 | 2021-2022 | |
| Vivus LLC | $192.09 | 2023-2025 | Pancreaze |
| Abbott Laboratories | $187.04 | 2025 | Esprit |
Show all 41 companies
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kevin Tin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.